Regulatory Updates, In Brief
FDA approves Acorda's MS drug: FDA approved Ampyra (dalfampridine) with the novel indication of improvement in walking ability in adults with multiple sclerosis, despite a questionably meaningful responder rate and increased risk of seizure. The Jan. 22 approval is a huge win for Acorda, which took a risk developing a MS drug with an indication that had never before been studied and for which there is no target for treatment. The approval also showcases FDA's confidence that the drug will provide a clinical benefit to some patients - a point of contention during Ampyra's advisory committee review. Despite showing that Ampyra patients had statistically significant faster walking speeds than those on placebo, FDA briefing documents noted that the magnitude of improvement was small and clinical significance was uncertain (1"The Pink Sheet," Oct. 26, 2009). Adding to the uncertainty was the drug's increased risk of seizures - a widely acknowledged safety signal for 4-aminopyridine and other pyridine compounds
Learn what's happening at the US FDA. On the go.
More from Archive
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
More from Pink Sheet
Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’
Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.
To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.